1. Home
  2. WHF vs GANX Comparison

WHF vs GANX Comparison

Compare WHF & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WHF

WhiteHorse Finance Inc.

HOLD

Current Price

$6.43

Market Cap

162.5M

Sector

Finance

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.80

Market Cap

159.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WHF
GANX
Founded
2011
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
162.5M
159.2M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
WHF
GANX
Price
$6.43
$1.80
Analyst Decision
Sell
Strong Buy
Analyst Count
2
6
Target Price
$7.75
$8.00
AVG Volume (30 Days)
108.4K
865.6K
Earning Date
03-06-2026
03-26-2026
Dividend Yield
16.02%
N/A
EPS Growth
N/A
N/A
EPS
0.42
N/A
Revenue
$76,339,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$15.23
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.39
$1.41
52 Week High
$11.31
$4.34

Technical Indicators

Market Signals
Indicator
WHF
GANX
Relative Strength Index (RSI) 30.81 32.04
Support Level $6.40 $1.61
Resistance Level $6.83 $2.07
Average True Range (ATR) 0.16 0.15
MACD -0.04 0.00
Stochastic Oscillator 8.30 5.66

Price Performance

Historical Comparison
WHF
GANX

About WHF WhiteHorse Finance Inc.

WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: